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Background: Young age breast cancers are quite prevalent in our setup, a significant number of which exhibit
triple negative phenotype. These cancers behave in an aggressive fashion and unresponsive to targeted adjuvant
therapy. We aimed to evaluate clinical and histopathologic features of triple negative cancers in our population.
Methods: We retrospectively evaluated 1104 cases of primary breast cancers. Immunohistochemical studies for ER,
PR and Her2neu followed by Her2neu gene amplification by FISH testing were done to identify 205 (18.6%) cases
of triple negative breast cancers.
Results: Mean age for triple negative breast cancer patients was 48.4 years (±12.3) and 60% of patients were diagnosed
at less than 50 years of age. Although ductal carcinoma was the most frequent histologic type, a meaningful number
of cases exhibited metaplastic and medullary like features (10.7% and 5.9% respectively). Similarly geographic necrosis
involving more than 40% of tumor and extensive lymphocytic infiltration was a considerable finding. Mean Ki67 index
was 45.2% (±25.2) and as a reflection of tumor grade, a significantly higher proportion of cases (66.3%) were under high
risk Ki67 category (>30%).
Conclusion: Triple negative breast cancers typify high grade breast cancers with a higher frequency of atypical medullary
and metaplastic histologies. Their prevailing occurrence at a younger age raises question of under lying BRCA mutations
in our population. Therefore, we suggest that risk factors including BRCA 1 mutations should be uncovered in
reproductive age group breast cancers especially those disclosing basal like phenotype.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
9042440621102239.
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Gene expression profiling studies put a new insight into
breast cancer classification beyond traditional histologic
sub-typing and grading. These newly defined luminal,
Her2neu and basal molecular subtypes of breast cancer
in addition to being a powerful indicator of prognosis
are also predictive of adjuvant hormonal and chemother-
apeutic response [1,2]. Among these, basal type breast
cancers are associated with worst prognostic and clinical
profile especially if not detected at an early age. They
comprise 15-20% of breast cancers and show low ex-
pression of ER, PR and Her2neu genes. Basal cancers* Correspondence: mehmoodkhan955@yahoo.com
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unless otherwise stated.derived its name by its origin from basal epithelial cells
of breast tissue and are thus typified by high expression
of basal epithelial cytokeratins [3]. Basal cancers are
affiliated with an abnormal DNA damage response path-
way with an ancillary elevated proliferation gene expression.
Although basal cancer subtype was originally defined by
gene expression profiling, however it was suggested that an
analogous ascertainment can be made by immunohis-
tochemical (IHC) techniques [4]. According to that
annotation, triple negativity for ER, PR and Her2neu
elucidate basal type breast cancers with high expres-
sion of basal cytokeratins [5]. Majority of triple nega-
tive breast cancers by IHC were found to be of basal like
phenotype by gene expression profiling, however Fluores-
cent Insitu hybridization (FISH) testing is recommended byl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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IHC expression of Her2neu [6].
Breast cancer is most frequent cancer of women in
Karachi, accounting for one-third of the cancers in the
females. The incidence of breast cancer is extremely
high in Karachi and second highest in Asia after Israel
[7]. A total of 698 cases of breast cancer were registered
from Karachi south over a duration of 3 years from
1995-1997 with a crude incidence rate of 33.1%. The
incidence of reproductive age breast cancer in karachi is
the highest reported globally [8].
Basal cancers have a unique demographic and racial
profile, with high rate of occurrence contemplated in
Asian and African American women [9]. A comparative
study conducted in United States revealed a higher fre-
quency of hormone receptor negative breast cancers in
Asian women compared to Caucasians [10]. Analogously
a higher frequency of basal cancers was also demon-
strated in Chinese women [11]. While the exact inci-
dence of basal cancers in Pakistani population is not
characterized, it is well established that frequency of
reproductive age breast cancer is considerably higher
than the western population [12,13]. As a reason for this
happening is not known and pathologic parameters of
younger age breast cancer is not well elucidated in our
setup, therefore we aimed to determine the frequency
and clinicopathologic parameters of triple negative breast
cancers in our population which usually show a targeted
racial and age preference.
Methods
We retrospectively analyzed 1104 cases of primary breast
cancers treated at Liaquat National Hospital from January
2010 till December 2012 over duration of 3 years. Approval
from institutional research and ethical review committee
was taken antecedent to conducting the study. Patients
after provisional diagnosis of breast cancer underwent
trucut biopsies, modified radical mastectomy and breast
conservative surgeries. All non–epithelial tumors were ex-
cluded from the study. Histologic type of tumors was deter-
mined by WHO classification of breast tumors and graded
by Modified Bloom-Richardson grading system. Immuno-
histochemical testing for ER, PR, Her2neu and Ki67 was
applied on all cases. A total of 158 out of 1104 cases were
negative with ER and PR antibodies and either negative or
weak (1+) positive with Her2neu antibody. Total 68 cases
were intermediate (2+) positive for Her2neu with negative
ER and PR. Therefore subsequent FISH testing was per-
formed on these 68 cases, out of which 19 cases showed
Her2neu gene amplification, 2 cases were equivocal and 47
cases were negative for Her2neu gene amplification.
One representative section from each tumor was se-
lected for immunohistochemical staining for ER, PR,
HER2neu and Ki67. Immunohistochemical testing wasdone by DAKO envision method according to manufac-
turers recommendations. The results for ER and PR
were scored in a semi quantitative fashion incorporating
both the intensity and the distribution of specific stain-
ing [14]. For each tissue a value designated as H-SCORE
was derived by summing up the percentage of cells
staining intensity multiplied by the weighted intensity of
staining. An H-SCORE of less than 50 was established as
negative, whereas an H-score of >50 is considered as
positive for ER and PR expression.
HER2neu were scored based on the intensity and per-
centage of positive cells on a scale of 0 to 3+. Cases were
reported 0 (negative) if no staining or membrane stain-
ing in less than 10% of invasive tumor cells was seen, 1+
(negative) if faint/barely perceptive membrane staining
was detected in more than 10% of invasive tumor cells,
2+ (positive) if weak to moderate complete membrane
staining in more than 10% tumor cells or <30% with
strong complete membrane staining, or 3+ (positive) if
strong complete membrane staining in more than 30%
invasive tumor cells was seen [15].
Ki-67 immunoreactivity was recorded as continuous
variables, based on the proportion of positive tumor cells
(0%-100%). Besides evaluating Ki-67 as continuous vari-
able, levels of Ki-67 were quantified as high Ki-67 (im-
munostaining ≥ 30%), low (immunostaining < 15%) and
intermediate (between 16 to 30%) approach adopted by
St Gallen International Expert Consensus [16,17].
Cases with intermediate (2+) expression of Her2neu
underwent subsequent FISH testing for Her2neu gene
amplification. FISH testing was performed using FDA
approved Path Vysion Her2 DNA Probe kit according.
Paraffin embedded tissues were cut at 5 microns and
mounted on positively charged glass slides. Four slides
were prepared, with one slide stained with H and E, the
selection of tissue and the identification of target areas
on the H and E stained slides was performed by a
pathologist. Using the H and E slide as reference, target
area was etched with a diamond tipped scriber on the
back of the unstained slide to be assayed. Glass slides
with paraffin embedded tissue sections were baked at
56C overnight. Tissue was then processed in xylene,
ethanol, purified water and wash buffer according to
manufacturer recommendations. Probe mixture was ap-
plied to the target area of the tissue on slide, sealed with
rubber cement and then incubated in thermobrite for
hybridization. After post-hybridization buffering, DAPI
(counter stain) was applied. Slides were analyzed by two
technologists, interpreting 60 interphase nuclei using
fluorescence microscope equipped with appropriate ex-
citation and emission filters allowing the visualization of
the orange and green fluorescent signals.
Results were expressed as the ratio of Her2 signals as
compared to CEP 17 signals according to ASCO/CAP
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sidered as absence of HER2 gene amplification. A HER2:
CEP 17 ratio from 1.8-2.2 was taken as equivocal and ratio
of >2.2 was considered gene amplification when there were
greater than 6 HER2 signals per nucleus.
Results
Out of 1104 cases of breast cancer identified during the
study period, 205 cases (18.6%) were triple negative for
ER, PR and Her2neu or non-amplified on Her2neu gene
amplification by FISH testing and therefore included in
the study. Out of these 205 cases, 110 patients under-
went primary surgery either radical or conservative while
in 95 cases trucut biopsy was done followed by neoadju-
vant therapy. Mean age for the patients was 48.4 years
(±12.3). A significant number of cases were diagnosed at
a younger age less than 50 years (60%). Very few cases
were at pT1 stage (12.7%), while most of them were
either pT2 or pT3. Although ductal carcinoma was the
most frequent histologic type, a meaningful number of
cases exhibited metaplastic and medullary like features
(10.7% and 5.9% respectively) (Figure 1). Similarly geo-
graphic necrosis involving more than 40% of tumor and
extensive lymphocytic infiltration was a considerable
finding. Mean Ki67 index was 45.2% (±25.2) and as a re-
flection of tumor grade, a significantly higher proportionFigure 1 Micrographs of carcinoma with medullary features. (a-c) Infiltrat
lymphoid infiltrate and syncytial growth pattern. (d) High Ki-67 index in tumof cases (66.3%) were under high risk Ki67 category
(>30%) as defined by St. gallen international expert con-
sensus recommendations. Lymph node metastasis and
lymphovascular invasion were seen in 48.2% and 27.3%
cases respectively. Detailed clinicopathologic characteristics
of the studied cases are presented in [Table 1]. Correlation
of tumor size with lymph node status, Ki67 index and
tumor grade are shown in [Table 2], which shows a positive
significant correlation between tumor size and lymph node
status. Correlation of Ki67 index with tumor size, lymph
node status and tumor grade are shown in [Table 3].
Discussion
Breast cancer is a heterogeneous disease encompassing
numerous distinct histologic and gene profile based sub-
types. Triple negative breast cancers represent one of
the most aggressive phenotype with discrete risk factors
and ominous prognostic significance. Our data repre-
sents the first study highlighting the clinical, histopatho-
logic and prognostic factors of basal like breast cancers
in our population.
Several studies evaluated the risk factors associated
with basal like breast cancers including age, race, ethni-
city, reproductive and parity history, breast feeding and
obesity. Trivers KF et. al in a study involving 476 pa-
tients evaluated socio-demographic and reproductiveing carcinoma with circumscribed pushing borders, dense peripheral
or cells.
Table 1 Clinicopathologic features of triple negative
breast cancers
Variable n = 205
Age at dignosis
Mean ± SD (years) 48.4 ± 12.3
Age specific groups, N (%)
< 30 years 15 (7.3%)
31-40 years 47 (22.9%)
41-50 years 61 (29.8%)
51-70 years 70 (34.1%)
> 70 years 12 (5.9%)
Tumor size
Mean ± SD (mm) 38.2 ± 16.2
Size specific groups, n (%)
≤ 2.0 cm (pT1) 14 (12.7%)
2.0-5.0 cm (pT2) 81 (73.6%)
> 5.0 cm (pT3) 15 (13.6%)
Without surgery/trucut biopsy$ 95
Histological type, n (%)
Infiltrating ductal carcinoma (NOS) 158 (77.1%)
Infiltrating lobular carcinoma 05 (2.4%)
Metaplastic carcinoma 22 (10.7%)
Invasive papillary carcinoma 07 (3.4%)
Infiltrating carcinoma with medullary features 12 (5.9%)
Missed ductal and lobular carcinoma 01 (0.5%)
Histologic grade, n (%)
Grade I (well differentiated)
Grade II (moderately differentiated)




Lymphovascular invasion, n (%)
Present
Not present




Geographic necrosis involving > 40% of tumor
Necrosis involving < 40% of tumor
Necrosis is absent 34 (30.9%)




Lymphocytic infiltration, n (%)
Extensive lymphocytic infiltration 21 (19.1%)
Table 1 Clinicopathologic features of triple negative
breast cancers (Continued)
Mild to moderate lymphocytic infiltration 89 (80.9%)
Cannot be completely assessed$ 95
Lymph node status, n (%)
Negative lymph nodes (N0) 57 (51.8%)
1-3 positive lymph nodes (N1) 24 (21.8%)
4-9 positive lymph nodes (N2) 11 (10.0%)
≥ 10 positive lymph nodes (N3) 18 (16.4%)
Lymph nodes dissection not done 95
Extranodal extension, n (%)
Present
Not present 15 (13.6%)




Mean ± SD (%) 45.2 ± 25.2







Type of surgery n (%)
Modified radical mastectomy
Breast conservation surgery







$Cases are of trucut biopsies without surgery.
Hashmi et al. Diagnostic Pathology 2014, 9:43 Page 4 of 9
http://www.diagnosticpathology.org/content/9/1/43characteristics of breast cancers. Their data revealed
that hormone receptor negative breast cancers were
associated with black race and young age at first birth.
They also affirmed that history of recent birth and
obesity as being risk factors for these cancers [18].
Phipps AL et al. suggested nulliparity as a protective
factor for triple negative breast cancer, although they
didn’t find a significant association with breast feeding
and oral contraceptive usage [19]. Risk factors for basal
like cancers were also explored in Carolina breast
cancer study. They found increased parity, younger age
at first term full-term pregnancy, longer duration of
breastfeeding, increasing number of children breastfed,
and increased duration of breastfeeding per child each
associated with an overall decrease in the risk of basal
Table 2 Correlation of tumor size with lymph node
status, Ki67 index and tumor grade
Sr. no. Tumor size
T1 T2 T3 p-value
1. Lymph node status
Positive 3 35 10 0.036
Negative 12 45 5
2. Ki67 index
Low 4 14 8
0.876Intermediate 3 18 49
High 8 49 8
3. Tumor grade
GII 2 11 4
0.422
GIII 13 70 11
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all these parameters in our study but we found a higher
frequency of basal like cancers in reproductive age
group women.
Some authors suggested that triple negative and basal
like breast cancers are not entirely similar entities. Basal
like cancer is a molecular defined category of breast can-
cer with expression of unique set of genes involving epi-
dermal growth factor (EFGR), basal cytokeratins (CK) 5/
6, proliferation gene clusters and low expression of hor-
mone and Her2neu genes [21]. Bertucci F evaluated gene
expression profile of 172 cases of triple negative breast
cancers and found 72% to express basal like phenotype
[22]. Gene expression profile separated out several sub-
types of triple negative cancers including two basal sub-
types, immunomodulatory, mesenchymal, mesenchymal
stem-like, luminal androgen, claudin-low and interferon-
rich subtypes [23-25]. How much these subtypes behave
differently clinically is yet to be fully understood, butTable 3 Correlation of Ki67 index with tumor size,
lymph node status and tumor grade
Sr. no. Ki67 index
Low Intermediate High p-value
1. Tumor size
T1 4 3 8 0.876
T2 14 18 49
T3 4 3 8
2. Lymph node status
Positive 8 14 26 0.245
Negative 14 10 38
3. Tumor grade
GI 3 1 6 0.180
GII 7 17 41
GIII 22 19 89chemotherapy is the main stay of treatment as they are
generally insensitive to targeted hormonal and herceptan
therapy. Phase II clinical trials are under way to fully
establish the potential role of anti-EFGR therapy in triple
negative breast cancers.
Kreike B et. al in a study involving 97 triple negative
cases of breast cancer evaluated clinical, histological and
molecular features. They found 59% of cases were below
50 years of age and 65% of tumors were above 2 cm in
maximum dimension. Although 83% of cases showed
typical ductal morphology but 3 cases were metaplastic
carcinomas. Concordant with our results vast majority
of tumors (86%) had high grade morphology and heavy
lymphocytic infiltrate was seen in only 12% of cases.
They also evaluated p53 and EFGR status and positivity
was seen in 50 and 27% of cases also pointing towards
aggressive nature of these tumors [26].
Fulford LG et. al suggested specific morphologic features
which were predictive of basal subtype. These included
central scar, tumor necrosis, presence of spindle cell or
squamous metaplasia, high total mitotic count (> 40 per 10
high-power fields) and high nuclear-cytoplasmic ratio [27].
We also found high grade morphology and tumor necrosis
in a significantly higher number of cases.
We found a higher frequency of metaplastic histology
in our study (Figures 2 and 3). Metaplastic carcinoma
itself is a heterogenous group of tumors including
sarcomatoid [28], squamous cell [29], adenosquamous
[30], mucoepidermoid, matrix producing [31], metaplas-
tic carcinoma with osteoclast like giant cells [32] and
low grade fibromatosis like spindle cell carcinoma [33].
We encountered 10 cases of adenosquamous carcinoma,
8 of matrix producing and 4 cases of sarcomatoid
carcinoma. These three categories are among the most ag-
gressive subtypes of metaplastic carcinoma, again pointing
towards the adverse morphologic characteristics of triple
negative tumors. Reis-Filho JS et. al in a study involving 65
cases of metaplastic carcinoma found 91% to be of basal
like phenotype irrespective of specific subtype [34]. Our
results are in agreement with these findings.
We also found 12 cases in our study with medullary
like features including high grade histology, lack of insitu
component, pushing borders, syncytial growth pattern
and dense lymphocytic infiltration (Figure 1). Gene ex-
pression profiling studies depicted this notion that me-
dullary like carcinomas belong to basal subgroup inspite
of being associated with a better prognosis [35].
Our study validated the strong association of triple
negative cancers with tumor grade and proliferative
index. Methodology of Ki67 index has not been stan-
dardized yet and different cut off points were used in
different studies to designate high Ki67 index (5-30%)
[36,37]. We therefore used 2 cut off points to stratify
Ki67 index into 3 categories; the approach advised by St.
Figure 2 Micrographs of metaplastic carcinoma, matrix producing type. (a-b) Tumor cells producing abundant myxoid matrix. (c)
Microphotograph showing high Ki-67 index.
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Ki67 index into three categories in our study, a signifi-
cantly higher proportion of triple negative cancers fell
under the umbrella of high risk Ki67 index (66.3%).
Spitale A. et al. in a study involving 90 basal cancers
also found similar association in Ticino breast cancer
registry based study with more than 75% of basal
cancers having Ki67 index greater than 20% [38]. This
observation is supported by high expression of prolif-
eration gene clusters seen in gene expression profiling
studies [39,40].
In our study, lymph node metastasis at the time of
diagnosis was found in 48.2% of cases. Vallejos et. al in a
study involving 255 basal like cancers found lymph node
positivity in 54.9% of cases [41]. Blows FM et. al in a
collaborative review of 1645 triple negative breast cancerFigure 3 Micrographs showing metaplastic carcinoma. (a-b) Matrix prosubdivided them into basal and non-basal phenotypes
on the basis of CK5/6 and EFGR positivity. In the basal
subgroup lymph node metastasis was seen in 40% of
cases while non-basal triple negative phenotype exhib-
ited lymph node metastasis in 46% of patients [42].
A morphologic study of basal cancers in Turkish
population revealed that all medullary and 55.6% of
metaplastic carcinomas showed basal phenotype which
is concordant with our findings. Moreover they found
an increased prevalence of basal cancers in younger age
group. Morphologic features associated with basal can-
cers in their study included high nuclear grade, in-
creased mitotic activity, geographic necrosis, pushing
border of invasion and stromal lymphocytic response.
Among IHC markers, vimentin was positive in 53.2%
and CK 14 in 27.7% of cases [43].ducing type with area of necrosis.
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tumors with slightly different prognostic profiles. There-
fore various markers were assessed to predict the prognosis
in triple negative cancers. Markers which were found to be
associated with poor prognostic profile in triple negative
cancers include CARM1, TTF1 and SBEM. Coactivator-
associated arginine methyltransferase 1 (CARM1) belongs
to protein arginine methyltransferase family. CARM1 was
found to be to be expressed in 57% of triple negative
cancers and was associated with high tumor grade [44].
Thyroid transcription factor 1 (TTF1) is marker of lung
and thyroid origin. Expression of TTF1 was also demon-
strated in basal phenotype breast cancers. TTF1 expression
was co-related with high tumor grade, lymph node metas-
tasis and vascular invasion [45]. Similarly small breast epi-
thelial mucin (SBEM) which has been implicated in tumor
genesis and micrometastasis in breast cancer is associated
with poor prognostic profile in triple negative breast cancer.
SBEM expression was found to be highly co-related with
higher tumor size, grade, nodal status, TNM stage and Ki67
index. Moreover multivariate analysis showed that patients
with high expression of SBEM had higher risk of tumor re-
currence and mortality [46]. Apart from IHC expression of
various markers, role of microRNAs (miRNAs) were also
evaluated in triple negative breast cancers. MiR-34b
negatively co-relates with disease free survival and over-
all survival in triple negative cancers [47]. Laurinavicius
A et. al evaluated multiple IHC markers in breast
cancer. They found a high expression of p16 in triple
negative breast cancers [48].
Gene expression profiling studies are not widely avail-
able in our country and cannot be performed on every
case of breast cancer. Immunohistochemical studies are
relatively less expensive and therefore can be performed
for initial segregation of cases into specific expression
profiles. Based on morphology and immunohistochemi-
cal profile, genetic studies can be performed to identify
at risk families as an effective preventive measure.
Risk factors for specific morphologic subtypes of breast
cancers have not been substantiated yet. Unlike smoking
induced squamous metaplasia which is considered a pre-
malignant change in bronchial epithelium, squamous
metaplasia in ductal epithelium of breast is not considered
pre-malignant. On the other hand, as most of the meta-
plastic carcinomas have been showed to harbor basal
phenotype, underlying BRCA mutations and familial
predisposition may play a role.
We analyzed 1104 breast cancer patients, out of which
205 cases exhibited triple negative phenotype with a fre-
quency of 18.6%. Compared to international data, only
Chinese, African Americans and Peruvians had a greater
frequency of triple negative cancers than ours with a
figure of 21.5%, 21.5% and 21.3% respectively [11,49].
The frequency of triple negative cancers in Caucasians,Australians and UK population was found to be low with
a frequency of 12.5%, 14% and 13% respectively [50,51].
Another significance of basal like breast cancers lies with
its association with BRCA 1 mutations. It was shown that,
more than 80% breast cancers occurring in women with
BRCA 1 mutation have a basal like profile. Although most
basal cancers are sporadic, they are also associated with an
abnormal BRCA 1 pathway [52-54]. Although young age
breast cancers are quite prevalent in our population, how-
ever genetic testing including BRCA mutations were not
widely done in our population. Therefore we suggest that
risk factors associated with triple negative breast cancers
especially those occurring in a younger age group with
metaplastic and medullary histologies should be sought
including underlying BRCA 1 mutations. In addition evalu-
ation of EFGR mutations and potential role of EFGR
therapy in basal like cancers should also be addressed.
Conclusion
Triple negative breast cancers typify high grade breast
cancers with a higher frequency of atypical medullary
and metaplastic histologies. Their prevailing occurrence
at a younger age raises question of under lying BRCA
mutations in our population. Therefore, we suggest that
risk factors including BRCA 1 mutations should be uncov-
ered in reproductive age group breast cancers especially
those disclosing basal like phenotype.
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